Advertisment

Biotech Industry Updates: Amgen and Regeneron's Obesity Treatments, Chinese Biotech Restrictions and Venture Capital Boost

author-image
Dr. Jessica Nelson
New Update
NULL

Biotech Industry Updates: Amgen and Regeneron's Obesity Treatments, Chinese Biotech Restrictions and Venture Capital Boost

Advertisment

Amgen's Obesity Drug: A Potential Game-Changer?

Advertisment

The biotech industry is currently ablaze with excitement over Amgen's experimental obesity drug, MariTide. MariTide has shown great potential in offering longer-lasting weight loss effects compared to current obesity drugs on the market. Amgen is currently testing a novel strategy with this drug candidate, aiming to determine if patients can be transitioned to lower or less frequent doses over time. Early data suggests promising results, with MariTide potentially providing a more sustained weight loss solution than other popular obesity drugs.

Amgen has already entered the weight loss market with MariTide, following a successful Phase I study on 133 obese but non-diabetic patients. The drug showed a significant 14.5% average weight reduction over 85 days, showing comparable weight loss to other popular drugs on the market and in development. The molecule also demonstrated a safety profile similar to GLP-1s, with the most common adverse events being mild cases of nausea and vomiting.

Regeneron's Approach to Obesity Treatment

Advertisment

Not to be outdone, Regeneron is also making strides in the obesity treatment landscape. The biotech giant is interested in developing a combo approach from its pipeline for obesity treatments, aiming to improve weight loss without substantial muscle loss, a concern that has been raised by Regeneron's CSO. This approach could potentially revolutionize the obesity treatment sector, offering a more holistic solution to obesity management.

Chinese Biotech Restrictions and Impact on the Market

However, not all is rosy in the biotech industry. A new congressional bill aimed at preventing federal agencies from contracting with a number of Chinese biotech companies has raised eyebrows and spooked investors. The potential restrictions have led to a sell-off of shares in various biotech companies, showing the significant impact policy changes can have on the market.

Advertisment

A Boost for Biotech Startups: ARCH Venture Partners

Despite the tumultuous market conditions, venture capital firm ARCH Venture Partners is proving its confidence in the industry by raising a $3 billion new fund. This fund is largely focused on startups targeting areas such as cancer, manufacturing, and psychiatric conditions. This significant investment could provide a much-needed boost for startups in the biotech sector, creating more opportunities for innovation and advancement in the field.

Other Notable Industry Developments

Aside from the major developments mentioned above, there are a few other notable events happening in the biotech sector. An initiative called Test Your Biomarkers aims to educate and raise awareness about the importance of testing for stomach cancer markers. The campaign, which was launched on World Cancer Day, is targeted at patients and their caregivers, with the goal of making biomarker testing a standard part of the diagnosis process for every stomach cancer patient.

Finally, the biotech industry has seen positive trends in early 2024, ranking second out of 197 industry groups tracked by IBD. Companies such as Amphastar Pharmaceuticals and ImmunoGen are leading in sales and earnings, showing the continued strength and potential of the biotech sector.

Advertisment
Chat with Dr. Medriva !